Ethics of gene therapy for wet AMD
Part of Eyes & vision clinical trials.
This study explores the ethical questions around using gene therapy for wet age-related macular degeneration (AMD). It is not a treatment trial, but a discussion study for patients whose doctors might consider gene therapy as an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wet (exudative) AMD
- You are over 18 years old
- Your doctor thinks gene therapy might be a possible treatment for you
- You do not have dry (atrophic) AMD
- You do not have other retinal diseases besides AMD
- You do not have significant cognitive problems that could affect participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy, EXG202, given as an injection into the eye. It aims to see if the treatment is safe and can help slow vision loss from wet AMD, a condition where abnormal blood vessels leak fluid under the retina.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
Hear when a new Exudative Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.